AI as a Novel Approach for Exploring ccfNAs in Personalized Clinical Diagnosis and Prognosis: Providing Insight into the Decision-Making in Precision Oncology

Lesetja Motadi; Mzubanzi Mabongo; Demetra Demetriou; Precious Mathebela; Zodwa Dlamini

doi:10.1007/978-3-031-21506-3_4

AI as a Novel Approach for Exploring ccfNAs in Personalized Clinical Diagnosis and Prognosis: Providing Insight into the Decision-Making in Precision Oncology

Lesetja Motadi, Mzubanzi Mabongo, Demetra Demetriou, Precious Mathebela, Zodwa Dlamini

Biochemistry

University of Pretoria

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

2 Citations (Scopus)

Abstract

For many years the idea of personalized medicine has toyed around. It is characterized as an innovative method to alter disease treatment and prevention that considers the differences in individuals’ genes and lifestyles. The purpose of precision medicine is to provide patient-specific treatments at the right time for quick and cost-effective recovery. While world technological advances provide the opportunity for many in medical science to access big data that no human brain can collate, the use of artificial intelligence (AI) may help improve cancer screening and diagnosis and planned treatment. In this chapter, although we will not cover all technologies already available for patient care, we highlight the progress made in using technology combined with liquid biopsy in precision oncology. We will also be discussing AI as a novel approach for exploring circulating cell-free nucleic acids (ccfNAs) in personalized clinical diagnosis and prognosis.

Original language	English
Title of host publication	Artificial Intelligence and Precision Oncology
Subtitle of host publication	Bridging Cancer Research and Clinical Decision Support
Publisher	Springer Nature
Pages	73-91
Number of pages	19
ISBN (Electronic)	9783031215063
ISBN (Print)	9783031215056
DOIs	https://doi.org/10.1007/978-3-031-21506-3_4
Publication status	Published - 1 Jan 2023

Keywords

Artificial intelligence
CcfNAs
Clinical decision-making
Diagnosis
Novel
Precision oncology
Prognosis

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-3-031-21506-3_4

Cite this

Motadi, L., Mabongo, M., Demetriou, D., Mathebela, P., & Dlamini, Z. (2023). AI as a Novel Approach for Exploring ccfNAs in Personalized Clinical Diagnosis and Prognosis: Providing Insight into the Decision-Making in Precision Oncology. In Artificial Intelligence and Precision Oncology: Bridging Cancer Research and Clinical Decision Support (pp. 73-91). Springer Nature. https://doi.org/10.1007/978-3-031-21506-3_4

@inbook{888f8665237b46e987c0223062c7c20c,

title = "AI as a Novel Approach for Exploring ccfNAs in Personalized Clinical Diagnosis and Prognosis: Providing Insight into the Decision-Making in Precision Oncology",

abstract = "For many years the idea of personalized medicine has toyed around. It is characterized as an innovative method to alter disease treatment and prevention that considers the differences in individuals{\textquoteright} genes and lifestyles. The purpose of precision medicine is to provide patient-specific treatments at the right time for quick and cost-effective recovery. While world technological advances provide the opportunity for many in medical science to access big data that no human brain can collate, the use of artificial intelligence (AI) may help improve cancer screening and diagnosis and planned treatment. In this chapter, although we will not cover all technologies already available for patient care, we highlight the progress made in using technology combined with liquid biopsy in precision oncology. We will also be discussing AI as a novel approach for exploring circulating cell-free nucleic acids (ccfNAs) in personalized clinical diagnosis and prognosis.",

keywords = "Artificial intelligence, CcfNAs, Clinical decision-making, Diagnosis, Novel, Precision oncology, Prognosis",

author = "Lesetja Motadi and Mzubanzi Mabongo and Demetra Demetriou and Precious Mathebela and Zodwa Dlamini",

note = "Publisher Copyright: {\textcopyright} The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.",

year = "2023",

month = jan,

day = "1",

doi = "10.1007/978-3-031-21506-3_4",

language = "English",

isbn = "9783031215056",

pages = "73--91",

booktitle = "Artificial Intelligence and Precision Oncology",

publisher = "Springer Nature",

address = "United States",

}

Motadi, L, Mabongo, M, Demetriou, D, Mathebela, P & Dlamini, Z 2023, AI as a Novel Approach for Exploring ccfNAs in Personalized Clinical Diagnosis and Prognosis: Providing Insight into the Decision-Making in Precision Oncology. in Artificial Intelligence and Precision Oncology: Bridging Cancer Research and Clinical Decision Support. Springer Nature, pp. 73-91. https://doi.org/10.1007/978-3-031-21506-3_4

AI as a Novel Approach for Exploring ccfNAs in Personalized Clinical Diagnosis and Prognosis: Providing Insight into the Decision-Making in Precision Oncology. / Motadi, Lesetja; Mabongo, Mzubanzi; Demetriou, Demetra et al.
Artificial Intelligence and Precision Oncology: Bridging Cancer Research and Clinical Decision Support. Springer Nature, 2023. p. 73-91.

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

TY - CHAP

T1 - AI as a Novel Approach for Exploring ccfNAs in Personalized Clinical Diagnosis and Prognosis

T2 - Providing Insight into the Decision-Making in Precision Oncology

AU - Motadi, Lesetja

AU - Mabongo, Mzubanzi

AU - Demetriou, Demetra

AU - Mathebela, Precious

AU - Dlamini, Zodwa

N1 - Publisher Copyright: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - For many years the idea of personalized medicine has toyed around. It is characterized as an innovative method to alter disease treatment and prevention that considers the differences in individuals’ genes and lifestyles. The purpose of precision medicine is to provide patient-specific treatments at the right time for quick and cost-effective recovery. While world technological advances provide the opportunity for many in medical science to access big data that no human brain can collate, the use of artificial intelligence (AI) may help improve cancer screening and diagnosis and planned treatment. In this chapter, although we will not cover all technologies already available for patient care, we highlight the progress made in using technology combined with liquid biopsy in precision oncology. We will also be discussing AI as a novel approach for exploring circulating cell-free nucleic acids (ccfNAs) in personalized clinical diagnosis and prognosis.

AB - For many years the idea of personalized medicine has toyed around. It is characterized as an innovative method to alter disease treatment and prevention that considers the differences in individuals’ genes and lifestyles. The purpose of precision medicine is to provide patient-specific treatments at the right time for quick and cost-effective recovery. While world technological advances provide the opportunity for many in medical science to access big data that no human brain can collate, the use of artificial intelligence (AI) may help improve cancer screening and diagnosis and planned treatment. In this chapter, although we will not cover all technologies already available for patient care, we highlight the progress made in using technology combined with liquid biopsy in precision oncology. We will also be discussing AI as a novel approach for exploring circulating cell-free nucleic acids (ccfNAs) in personalized clinical diagnosis and prognosis.

KW - Artificial intelligence

KW - CcfNAs

KW - Clinical decision-making

KW - Diagnosis

KW - Novel

KW - Precision oncology

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85160159240&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-21506-3_4

DO - 10.1007/978-3-031-21506-3_4

M3 - Chapter

AN - SCOPUS:85160159240

SN - 9783031215056

SP - 73

EP - 91

BT - Artificial Intelligence and Precision Oncology

PB - Springer Nature

ER -

Motadi L, Mabongo M, Demetriou D, Mathebela P, Dlamini Z. AI as a Novel Approach for Exploring ccfNAs in Personalized Clinical Diagnosis and Prognosis: Providing Insight into the Decision-Making in Precision Oncology. In Artificial Intelligence and Precision Oncology: Bridging Cancer Research and Clinical Decision Support. Springer Nature. 2023. p. 73-91 doi: 10.1007/978-3-031-21506-3_4

AI as a Novel Approach for Exploring ccfNAs in Personalized Clinical Diagnosis and Prognosis: Providing Insight into the Decision-Making in Precision Oncology

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this